Entering text into the input field will update the search result below

Zynerba up 17% premarket on new cannabidiol gel patent

  • The USPTO has issued a new patent, No. 10,213,390, to Zynerba Pharmaceuticals (NASDAQ:ZYNE) covering the use of its cannabidiol transdermal gel (ZYN002) to treat Fragile X syndrome, an inherited disorder characterized by learning disabilities and cognitive impairment.  Shares are up 17% premarket on increased volume.

Recommended For You

Related Stocks

SymbolLast Price% Chg
ZYNE--
Zynerba Pharmaceuticals, Inc.